返回 
加入收藏
我国医院糖尿病药物治疗及基本药物应用
x
请在关注微信后，向客服人员索取文件
| 篇名： | 我国医院糖尿病药物治疗及基本药物应用 |
| TITLE： | |
| 摘要： | 目的：分析我国医院糖尿病药物治疗及基本药物应用情况，为药物政策制定和糖尿病防控提供相关依据。方法：利用艾美仕中国医院药品采购数据库2012－2014年糖尿病药物年度消耗数据，分析胰岛素及其类似物和口服降糖药消耗量占前60％的目标药物情况，以及我国医院两种给药方式胰岛素及其类似物和三代胰岛素的消耗量、消耗金额占比。结果与结论： 北京拜耳医药保健有限公司生产的阿卡波糖片和上海施贵宝制药有限公司生产的二甲双胍片一直占据着我国医院口服降糖药消耗量的前两位，总计占25％～26％。胰岛素及其类似物60％的消耗量集中在1个价格低廉的国产动物胰岛素（消耗量占13％～16％，消耗金额占1％），以及跨国制药公司或合资企业生产以笔针/笔芯为给药方式的二、三代人胰岛素及其类似物。无论是胰岛素及其类似物还是口服降糖药，消耗量占比排名第一的产品都纳入了我国《国家基本药物目录》，但都不是世界卫生组织收录的基本药物。众多跨国制药公司通过不断推出新复方制剂和新剂型主导了我国糖尿病药物市场。未被世界卫生组织收录为基本药物的品种在我国医院销售情况良好，而供应普通人群的传统低价降糖药消耗量增长缓慢。我国医院总体上消耗了较多价格偏高的新一代和原研糖尿病药。我国作为刚刚建立起全民基本医疗保障体系的中低收入国家，还有广大人群仍处于较低医疗保障水平，提高宝贵医药卫生资源的使用效率对我国医改成效和卫生体系的可持续发展至关重要。 |
| ABSTRACT： | OBJECTIVE： To analyze the treatment of anti-diabetics medicines and use of essential medicines in Chinese hospital， and provide evidence for developing medicine policy， preventing and treating diabetes. METHODS： Data about annual consumption from 2012 to 2014 were extracted from the IMS CHPA database to analyze the object medicines of the target drugs with top 60％ consumption volume of oral anti-diabetics and insulins， and the proportion of consumption volume and consumption amount in insulin， its analogues and three generations of insulin by 2 administration mode in Chinese hospital. RESULTS & CONCLUSIONS： Acarbose tablet manufactured by Beijing Bayer HealthCare Co.， Ltd. and Metformin tablet manufactured by Shanghai Squibb Pharmaceutical Co.， Ltd. had occupied the top 2 of volume consumption in Chinese hospitals， totally accounting for 25％-26％. The 60％ volume consumption of insulins and its analogues concentrated on one cheap local animal insulin （volume accounting for 13％-16％ and amount accounting for 1％） and those imported or joint venture-made the second and third generation of insulins and analogues administrated by pen/cartridge. No matter insulins or oral anti-diabetics， the top consumption was listed as National Essential Medicine System， but none was recommended by WHO. Multi-pharmas dominate the Chinese anti-diabetic market through introducing new combined formulations and new dosage forms. WHO non-listed anti-diabetics have beautiful sales in Chinese hospitals， while traditional cheap medications for the general public grew slowly and with low profits. Chinese hospitals generally consumed more expensive new generations and original research manufacturers of anti-diabetics. As a lower middle income country that just established a universal coverage of basic health insurance， China still has a huge population with very limited benefit package. Efficient use of limited health resources is essential for a successful health reform and a sustainable development of the health system in China. |
| 期刊： | 2016年第27卷第24期 |
| 作者： | 孙静，罗仁 |
| AUTHORS： | SUN Jing，LUO Ren |
| 关键字： | 糖尿病药物；消耗量；消耗金额 |
| KEYWORDS： | Anti-diabetics； Consumption volume； Consumption amount |
| 阅读数： | 475 次 |
| 本月下载数： | 6 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
